The Phase 4 study conducted by Universidad Nacional de Rosario aims to validate the effectiveness of a reminiscence program in enhancing the quality of life for long-term care residents with Alzheimer's disease. Given the increasing prevalence of Alzheimer's and the growing demand for effective non-pharmacological interventions, this study could position reminiscence therapy as a viable treatment option in the dementia care market. The results may influence market dynamics by providing evidence for reimbursement and adoption in care facilities, potentially impacting competitors focused on pharmacological solutions. Stakeholders should consider the implications of these findings for future product development and partnerships in the geriatric care sector.